Want to see ENGN full AI Analyst Report?
ENGN Stock Chart & Stats
$8.07
$0.17(2.19%)
At close: 4:00 PM EST
$8.07
$0.17(2.19%)
Day’s Range― - ―
52-Week Range$1.40 - $12.25
Previous CloseN/A
Volume16.79K
Average Volume (3M)3.00M
Market Cap
$119.24M
Enterprise Value$67.50M
Total Cash (Recent Filing)$258.46M
Total Debt (Recent Filing)$33.35M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Sep 16, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding66,989,460
10 Day Avg. Volume954,761
30 Day Avg. Volume2,997,310
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-182.93
Enterprise Value/Ebitda-0.54
Forecast
1Y Price Target
$3.00Price Target Upside-62.83% Downside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)-1.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash Balance & Low LeverageA cash position of ~$285M and historically low debt-to-equity (~0.12 TTM) provide meaningful runway for late-stage development and BLA preparation. This financial flexibility lowers immediate dilution pressure, supports regulatory interactions and pre-commercial activities, and buys time to validate pivotal data.
Promising Pivotal Efficacy And Regulatory DesignationsA 54% complete response and low progression rate in high-risk BCG-unresponsive NMIBC underpin a credible path to approval. Coupled with RMAT and Fast Track designations and FDA CMC pilot inclusion, these factors materially improve regulatory engagement, potentially accelerating review and increasing the odds of a viable BLA submission.
Differentiated Non-viral Platform And AdministrationGenEdit's non-viral delivery and potential surfactant-enhanced administration create a structural competitive edge: lower immunogenicity, outpatient office-based delivery suitable for community urology (~80% of care), and mechanistic levers to improve efficacy, supporting broader adoption and easier commercialization if durability improves.
Bears Say
Pre-revenue With Accelerating Cash BurnPersistent and growing negative operating and free cash flows mean the company remains dependent on external funding to complete pivotal work and commercial prep. Even with a strong cash balance, continued high burn raises dilution risk, can constrain strategic choices, and increases execution pressure to demonstrate clinical success quickly.
Major Restructuring And Senior Leadership TurnoverA 50% headcount reduction and departures among key executives at a late-stage juncture create material execution risk. Loss of operational capacity and institutional knowledge may slow regulatory, clinical and pre-commercial tasks, complicate FDA interactions and compress timelines during a critical BLA-preparation period.
Durability Concerns In Pivotal DataSubstantial drop-off in durability metrics versus initial responses raises questions on long-term clinical benefit. If 12-month durability proves low, the FDA could require additional evidence or narrower labeling, and commercial uptake may be limited without improvements from surfactant cohorts, leaving regulatory and market risk unresolved.
enGene Holdings News
ENGN FAQ
What was Engene Holdings Inc.’s price range in the past 12 months?
Engene Holdings Inc. lowest stock price was $1.40 and its highest was $12.25 in the past 12 months.
What is Engene Holdings Inc.’s market cap?
Engene Holdings Inc.’s market cap is $119.24M.
When is Engene Holdings Inc.’s upcoming earnings report date?
Engene Holdings Inc.’s upcoming earnings report date is Sep 16, 2026 which is in 75 days.
How were Engene Holdings Inc.’s earnings last quarter?
Engene Holdings Inc. released its earnings results on Jun 15, 2026. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.466 by $0.036.
Is Engene Holdings Inc. overvalued?
According to Wall Street analysts Engene Holdings Inc.’s price is currently Overvalued.
Does Engene Holdings Inc. pay dividends?
Engene Holdings Inc. pays a Quarterly dividend of $0.13 which represents an annual dividend yield of N/A. See more information on Engene Holdings Inc. dividends here
What is Engene Holdings Inc.’s EPS estimate?
Engene Holdings Inc.’s EPS estimate is -0.44.
How many shares outstanding does Engene Holdings Inc. have?
Engene Holdings Inc. has 66,989,460 shares outstanding.
What happened to Engene Holdings Inc.’s price movement after its last earnings report?
Engene Holdings Inc. reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.466. Following the earnings report the stock price went up 9.259%.
Which hedge fund is a major shareholder of Engene Holdings Inc.?
Currently, no hedge funds are holding shares in ENGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
enGene Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (-62.83% Downside)
$3.00 (-62.83% Downside)
Blogger Sentiment
Bullish
ENGN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 41.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.0%
Last 30 Days ▼ 15.9%
Last 30 Days ▼ 15.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.38%
12-Months-Change
Fundamentals
Return on Equity
-29.34%
Trailing 12-Months
Asset Growth
15.33%
Trailing 12-Months
Company Description
Engene Holdings Inc.
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
ENGN Stock 12 Month Forecast
Average Price Target
$3.00
▼(-62.83% Downside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Replimune Group
―
Immuneering
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
4.47%
Insiders
0.73% Mutual Funds
― Other Institutional Investors
94.81% Public Companies and
Individual Investors